Press release
Diabetes Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | vTv Therapeutics, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Celon Pharma, Sciwind Biosciences,
Diabetes Pipeline Insights
Diabetes Overview:
Diabetes is a chronic metabolic condition marked by elevated blood sugar levels due to the body's inability to produce or properly use insulin, a hormone necessary for regulating glucose. The two main types are Type 1 diabetes, an autoimmune disease where the immune system attacks insulin-producing cells in the pancreas, and Type 2 diabetes, which is more common and typically linked to insulin resistance and lifestyle factors like obesity and poor diet. Other forms of diabetes include gestational diabetes, which occurs during pregnancy, and rarer types such as Maturity-Onset Diabetes of the Young (MODY) and Latent Autoimmune Diabetes in Adults (LADA).
The symptoms of diabetes can vary depending on the type and severity, but common signs include excessive thirst and frequent urination as the body attempts to remove excess glucose. Other symptoms may include intense hunger, unintentional weight loss, fatigue, and blurred vision due to fluctuating blood sugar levels. In Type 2 diabetes, slow-healing wounds, frequent infections, and tingling or numbness in the hands and feet, often indicating nerve damage, are also common.
Request for a detailed insights report on Diabetes pipeline insights @ https://www.delveinsight.com/report-store/diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Diabetes Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Diabetes Therapeutics Market.
Key Takeaways from the Diabetes Pipeline Report
DelveInsight's Diabetes pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Diabetes treatment.
In November 2024, GIOSTAR announced that it received FDA clearance for its Investigational New Drug (IND) application to begin a Phase 2 clinical trial for the development of a targeted stem cell therapy for Type II Diabetes.
In January 2024, Glenmark Pharmaceuticals Ltd., a global research-driven pharmaceutical company, introduced a biosimilar of the widely used anti-diabetic drug Liraglutide in India for the first time.
Key Diabetes companies such as vTv Therapeutics, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical, and others are evaluating new drugs for Diabetes to improve the treatment landscape.
Promising Diabetes pipeline therapies in various stages of development include Cadisegliatin, LY-3209590, THDB0206, CPL207280, XW014, KN056, and others.
Diabetes Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Diabetes Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetes treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Diabetes market.
Download our free sample page report on Diabetes pipeline insights @ https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Diabetes Emerging Drugs
Cadisegliatin: vTv Therapeutics
LY-3209590: Eli Lilly and Company
THDB0206: Tonghua Dongbao Pharmaceutical
CPL207280: Celon Pharma
XW014: Sciwind Biosciences
KN056: Suzhou Alphamab Co., Ltd.
Diabetes Companies
Over 200 major companies are working on developing therapies for diabetes. Among them, vTv Therapeutics, Eli Lilly and Company, and Tonghua Dongbao Pharmaceutical have drug candidates in the most advanced stage of development, Phase III.
DelveInsight's report covers around 200+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Diabetes Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Diabetes Therapies and Key Companies: Diabetes Clinical Trials and advancements @ https://www.delveinsight.com/report-store/diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Diabetes Pipeline Therapeutic Assessment
• Diabetes Assessment by Product Type
• Diabetes By Stage
• Diabetes Assessment by Route of Administration
• Diabetes Assessment by Molecule Type
Download Diabetes Sample report to know in detail about the Diabetes treatment market @ Diabetes Therapeutic Assessment @ https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Diabetes Current Treatment Patterns
4. Diabetes - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Diabetes Late-Stage Products (Phase-III)
7. Diabetes Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Diabetes Discontinued Products
13. Diabetes Product Profiles
14. Diabetes Key Companies
15. Diabetes Key Products
16. Dormant and Discontinued Products
17. Diabetes Unmet Needs
18. Diabetes Future Perspectives
19. Diabetes Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights Diabetes the diabetes Pipeline Reports Offerings: https://www.delveinsight.com/report-store/diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetes Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | vTv Therapeutics, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Celon Pharma, Sciwind Biosciences, here
News-ID: 3818746 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Diabetes
Major Force in the Diabetes Pen Market 2025: Diabetes Fuels Surge In Demand For …
How Will the Diabetes Pen Market Grow, and What Is the Projected Market Size?
The diabetes pen market is projected to grow from $29.24 billion in 2024 to $31.22 billion in 2025, at a CAGR of 6.8%. Growth is fueled by the rising need for managing diabetes, advancements in diabetes care, and an increasing focus on patient-friendly medication administration tools.
The diabetes pen market is projected to grow strongly, reaching $40.17 billion…
Diabetes Monitoring Devices Market: Regaining Its Glory| Ascensia Diabetes Care, …
The Latest Study Published by HTF MI Research on the "Diabetes Monitoring Devices Market'' evaluates market size, trend and forecast to 2029. The Diabetes Monitoring Devices market study includes significant research data and evidences to be a practical resource document for managers and analysts is, industry experts and other key people to have an easily accessible and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges…
Prevalence of Diabetes Drives Opportunities for Type-2 Diabetes Market
The Type-2 Diabetes Market Analysis, 2023, by MarkNtel Advisors, presents a well-researched, detail-driven, and accurate study for the stakeholders. This analysis entails prominent aspects like trends, & recent developments, drivers, opportunities, challenges, & restraints, among other parameters, influencing the overall industry expansion across different locations. This report comprises data from historic years (2018-21) & the base year (2022) to put together an estimation of the forecast period (2023-28).
According to Type-2 Diabetes Market…
Reverse Diabetes with Dr. Merritt’s Diabetes Reversal Recipe
[November 26, 2020] – People suffering from diabetes always search for ways to lower blood sugar levels in their bodies. Diabetes treatment available costs you hundreds of dollars yearly and also restricts you to a diabetic diet. That hampers your mental health and well-being. Apart from this, eye problems, kidney failure, amputations are some of the physical problems diabetic patients face.
Dr. Marlene Merritt (from the Merritt Wellness Center in…
Emerging trends for Diabetes Care Devices Market 2020 astonishing growth by Worl …
The global diabetes care devices market is expected to reach US$ 39,382.3 Mn in 2027 from US$ 23,354.3 Mn in 2018. The market is estimated to grow with a CAGR of 6.1% from 2020-2027.
Premium market insights recently published a report titled "Diabetes Care Devices Market Size and Forecast to 2026". The report includes an authentic and accurate research study into the global Diabetes Care Devices market based on a qualitative…
Diabetes Treatment
Diabetes Treatment is a important way to help manage the healthy ,easy to use and improve the way of the treatment of blood glucose monitoring system.
As living standards improve, an increasing obesity, the Diabetes Treatment has improved peoples living habits, disease control effect, is becoming more and more important.
The global Diabetes Treatment market is valued at 43700 million US$ in 2018 and will reach 58000 million US$ by the end…
